CIK 0001576885 · <br>Emerging growth company
Acumen Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ABOS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364108129
- Phone
- 617-344-4190
- Business address
- 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON, MA, 02465
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-06 | Sands Capital Ventures Discovery Fund III, L.P. 10% owner | Conversion · Series B Preferred Stock | −1,842,346 | 0 | ||
| 2021-06-30 | Stoppel Laura Director | Grant or award · Stock Option (Right to Buy) | +34,000 | 34,000 | ||
| 2021-06-30 | Stalfort John A III Director | Grant or award · Stock Option (Right to Buy) | +34,000 | 34,000 | ||
| 2021-06-30 | Sevigny Jeffrey Director | Grant or award · Stock Option (Right to Buy) | +34,000 | 34,000 | ||
| 2021-06-30 | Ives Jeffrey L. Director | Grant or award · Stock Option (Right to Buy) | +34,000 | 34,000 | ||
| 2021-06-30 | Fountain Nathan B Director | Grant or award · Stock Option (Right to Buy) | +34,000 | 34,000 |
Page 13 of 13 · 246 trades